Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 25 October 2021

Date: 25/10/2021
Location: Online

This extraordinary plenary meeting is organised in the context of the evaluation of an application for the use of a booster dose for the COVID-19 vaccine Spikevax.

The aim of the meeting is to conclude this evaluation, if possible.

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the Agency's opinions on all questions concerning human medicines. 

Related content

How useful was this page?

Add your rating
Average
1 rating